These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 24410765

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
    Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H.
    Cancer; 2007 Aug 15; 110(4):791-800. PubMed ID: 17582802
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
    O'Hara J, Vareslija D, McBryan J, Bane F, Tibbitts P, Byrne C, Conroy RM, Hao Y, Gaora PÓ, Hill AD, McIlroy M, Young LS.
    Clin Cancer Res; 2012 Jun 15; 18(12):3305-15. PubMed ID: 22550166
    [Abstract] [Full Text] [Related]

  • 32. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A.
    Breast Cancer Res Treat; 1999 Sep 15; 57(2):183-92. PubMed ID: 10598045
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth.
    Liang YJ, Hao Q, Wu YZ, Wang QL, Wang JD, Hu YL.
    Int J Gynecol Cancer; 2009 Oct 15; 19(7):1248-52. PubMed ID: 19823063
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
    Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R, Mehta RG.
    J Steroid Biochem Mol Biol; 2013 Jan 15; 133():30-42. PubMed ID: 22939887
    [Abstract] [Full Text] [Related]

  • 37. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM.
    Cancer Res; 2013 Jun 15; 73(12):3783-95. PubMed ID: 23650283
    [Abstract] [Full Text] [Related]

  • 38. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
    Masri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S.
    Breast Cancer Res Treat; 2010 Nov 15; 124(1):89-99. PubMed ID: 20054641
    [Abstract] [Full Text] [Related]

  • 39. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
    Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A.
    Cancer Res; 2009 Feb 15; 69(4):1416-28. PubMed ID: 19190349
    [Abstract] [Full Text] [Related]

  • 40. Intratumoral aromatase model: the effects of letrozole (CGS 20267).
    Brodie A, Lu Q, Yue W, Wang J, Liu Y.
    Breast Cancer Res Treat; 1998 Feb 15; 49 Suppl 1():S23-6; discussion S33-7. PubMed ID: 9797014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.